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Abstract 
Neurotrophin expression in early stages of development is crucial for brain assembly and 
function. In particular, postnatal expression of neurotrophins has not been well documented 
in the neostriatum and in general neurotrophins or their receptor mRNA’s are normally 
reported, but not protein expression. In the present study, immunocytochemical expression 
of BDNF, NT-3 and NT-4/5 was characterized in striatal tissue of C57BL/6 mice at postnatal 
days 10
th (P10), 21
st (P21), 42
nd (P42) and 80
th (P80).   
We found that the expression of BDNF diminished along the postnatal time course we 
evaluated, while staining for NT-4 increased up to age P42 and remained constant, thereafter 
in the cell’s soma. In contrast, NT-3 was first expressed in the neostriatal bundles and later 
on, in neostriatal cell somas. These results provide information about differences in the spa-
tial and temporal expression of each neurotrophin in the neostriatum during the first 80
th 
postnatal days. 
RT-PCR procedures were also carried out to further determine whether protein levels of 
neurotrophins observed in the neostriatum were under control of gene expression. All 
neurotrophin mRNAs were expressed and only mRNA
BDNF was reduced during the post-
natal evaluated days. 
Differences in temporal expression of neurotrophins may be related to the heterochronic 
development of neostriatal cell populations, but also with the specificity of each neurotro-
phin modulating different neuronal targets.   
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Introduction 
Neurotrophins are a family of trophic factors 
involved in differentiation and survival of neural cells 
[1]. Neural Growth Factor (NGF), Brain Derived 
Neurotrophic Factor (BDNF), Neurotrophin 3 (NT-3) 
and Neurotrophin 4/5 (NT-4/5) are active in different 
neuronal groups throughout the embryonic period 
but sometimes their roles are restricted to a specific 
developmental stage [2].  
Neurotrophin distribution is not homogeneous 
throughout the nervous system and its expression is 
low during postnatal period [ 3 ] .  I n  m i c e  s t r i a t u m ,  
neurotrophin expression is important for the estab-
lishment of neuronal connections as well as its correct 
cell functions. Previous studies have established 
messenger RNA (mRNA) expression of NGF [4], 
BDNF [5-7], NT-3 [7, 8] and NT-4/5 [9] in neostriatal Int. J. Biol. Sci. 2009, 5 
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tissue, although these molecules have not always been 
detected by Northern blot in fetal or postnatal brain 
[10]. In addition to the presence of neurotrophin 
mRNA, expression of neurotrophin receptors have 
been documented during the early development of 
the striatum [3, 7, 8, 11-13]. Nonetheless, the 
time-course of postnatal expression of neurotrophins, 
has not been well recognized in the striatum. Neu-
rodegenerative disorders affecting the central nervous 
system are characterized by cell death of specific 
neuronal populations. Some degenerative diseases 
afflicting neural system have clear genetic origin [14]; 
however most of them are sporadic, suggesting that 
other mechanisms are influencing this outcome. Stri-
atal neurons are particularly sensitive to excitotoxicity 
[15] and metabolic insults [16]; additionally, trophic 
factors can supply deficits during the first two post-
natal weeks that may worsen cellular harm. As neu-
rodegenerative diseases may be a consequence of 
abnormal levels of neurotrophins during the first 
stages of development, a clear description of their 
expression patterns during the two postnatal months 
in the normal brain is important to address before 
evaluating them in striatal dysfunction.  
  We aim to describe postnatal expression of 
neurotrophin proteins visualized with immunostain-
ing techniques at P10, P21, P42, and P80 in C57BL/6 
mice. To further verify whether neurotrophin protein 
expression is determined by gene expression, we 
examined the mRNA levels of each neurotrophin at 
P10, P21 and P42 in mice striatum.   
Materials and Methods 
  Male C57BL/6 mice (Harlan, México) of 10th, 
21st, 42nd, and 80th postnatal days were euthanized 
with pentobarbital (45mg/kg of body weight) and 
heart perfused with saline solution (NaCl 0.15 M) 
followed by phosphate-buffered saline (PBS, 0.1M, 
pH 7.4) with paraformaldehyde (4%). Brains were 
dissected and post-fixed in the same fixative for two 
hours at room temperature, and then transferred to a 
sucrose solution (30%) until they sank for cryoprotec-
tion. The brains were frozen in cold 2-methylbutane. 
Cryostat coronal sections (30 μm) containing dorsal 
striatum were cut and collected sequentially into 
24-well dishes filled with blocking solution for im-
munocytochemistry (3% bovine serum albumin, 0.1% 
triton X-100 and 0.025% sodium azide in PBS).  
All animal procedures were carried out with the 
approval of the animal care committee of the National 
Autonomous University of México and in agreement 
with the NIH. 
Immunocytochemistry (IHC) 
Tissue sections were incubated in blocking se-
rum overnight at 4° C. After that, tissue slices were 
incubated with primary antibodies against BDNF, 
NT-3, and NT-4/5 (cat # AB1534SP, AB1517P, 
AB1519P, respectively, Chemicon International, Inc.), 
diluted all (1:1000) in blocking buffer and incubated 
for 24 hours at 4° C. Three washes were done with 
blocking solution (every 15 min), then tissue slices 
were incubated for 90 minutes at room temperature 
with the corresponding biotinylated secondary anti-
bodies (Vector Laboratories, Burlingame, CA, USA) 
diluted (1:500) in blocking solution. After three 
washes with PB, slices were incubated with the 
avidin-peroxidase kit as recommended by the sup-
plier (ABC kit; Vector). Peroxidase activity was re-
vealed and intensified by using 3, 3’-diamobenzidine 
as a chromogen and nickel chloride according to the 
protocol provided by the supplier (Peroxidase stain-
ing kit; Vector). Finally, the staining was stopped after 
~5 minutes by washing the slices with PB. For control 
IHC staining, the primary antibody was omitted and 
the tissue sections were processed with the same 
procedure as described before. Slices were mounted 
on gelatin-coated slides and cover slipped with Per-
mount (Fisher, Inc).  
Quantitative assessment of neurotrophins ex-
pression in the striatum 
Images of immunostained sections of dorsal 
neostriatum, from animals of 10 (n=10), 21 (n=10), 42 
(n=10), 80 (n=10) days old were captured and quanti-
fied using an imaging analyses system (Image J sys-
tem, NIH). For each mouse, six striatal slices (30 μm 
thick) spaced at intervals of 180 μm were taken and 
processed for immunocytochemistry. Afterwards, 
p o s i t i v e  c e l l s  o f  f o u r  s e l e c t e d  f i e l d s  ( 2 5 2  μm2, area) 
were counted in digitized images taken at the level of 
dorsal striatum. Each image slice was digitized using 
a computer assisted system consisting of a Nikon Op-
tiphot microscope and a digital camera connected to a 
Pentium computer equipped with the morphometric 
software analysis. Contrast and area values were kept 
constant and intensity threshold was established to 
eliminate background staining. The number of cells 
counted per field was averaged per animal and then 
per group and compared using variance analysis with 
a significance value of p <0.05. Post hoc Bonferroni´s 
comparisons were done when significance was ob-
served. Data are expressed in mean ± S.E.M Int. J. Biol. Sci. 2009, 5 
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RNA extraction and Reverse Transcriptase 
(RT)-Polymerase Chain Reaction (PCR) 
Total RNA was isolated from 0.5 g samples of 
frozen mice striatal tissue. The extraction was carried 
out with the TRIzol reagent method using the Total 
RNA Isolation Reagent (Invitrogen, Life Technologies, 
Inc.). RNA concentration was calculated from the op-
tical density at 260 nm and the purity was determined 
by 260nm /280nm of absorbance [17]. 
  Total RNA (~300ng) from each sample was re-
verse transcribed and amplified with polymerase 
chain reaction with gene-specific for NGF, BDNF, 
NT-3, NT4/5 and β-actin, using the Super Scrit II kit 
(Invitrogen, Life Technologies, Inc.). Reverse Tran-
scription was performed with a TECHNE, TC 3000 
thermocycler. 2 μl of each RT product obtained was 
amplified with PCR using the RED Taq DNA Poly-
merase (Sigma-Aldrich, Inc.) in a final volume of 20 μl 
and 0.5 μl of each specific neurotrophin primer. The 
amplification cycles and the primers are specified in 
the Table 1. For the semi–quantitative analysis of 
RT-PCR products, β-actin was used as an internal 
control [18, 19]. Total PCR products were detected by 
electrophoresis on a 2% agarose gel and stained with 1 
μl de SYBR Green. The area and density of PCR 
product bands were measure d  b y  c h e m i o  l u m i n e s -
cence using a FUJIFILM FLA-5000 scanner and digi-
tized with the Image Reader FLA-5000 V2.1 program. 
The levels of β-actin mRNA served as an internal 
standard to ensure equal loading of RNA, then neu-
rotrophin mRNA levels were normalized with the 
housekeeping gene. The resulting measures were ex-
pressed as arbitrary densitometry units and statisti-
cally analyzed.   
Table 1. Primers used for the PCR 
Neurotrophin Sequence  Cycles  Product  (bp)  ºC 
Sense 5'-TAGCGTAATGTCCATGTTGT  NGF 
Antisense 5'-CCCACACACTGACACTGTCA 
35 434  58 
Sense 5'-GAAGAGCTGCTGGATGAGGAC  BDNF 
Antisense 5'-TTCAGTTGGCCTTTTGATACC 
35 332  60 
Sense 5'-CTCATTATCAAGTTGATCCA  NT-3 
Antisense 5'-CCTCCGTGGTGATGTTCTATT 
35 312  55 
Sense 5'-CCCTGCGTCAGTACTTCTTCGAGAC  NT-4/5 
Antisense 5'-CTGGACGTCAGGCACGGCCTGTTC 
35 249  65 
Sense 5'-TGGTGGGTATGGGTCAGAAGGACTC  β-actin 
Antisense 5'-CATGGCTGGGGTGTTGAAGGTCTCA 
35 266  60 
Primer sequences were designed according to ref [19]. All primers were obtained from Sigma-Alrdrich 
 
Statistical Analysis 
Data are presented as mean ± S.E.M values if 
anything else is indicated. For IHC and RT-PCR ex-
periments groups were compared using variance 
analysis, p <0.05 were considered to be statistically 
significant. Post hoc Bonferroni´s comparisons were 
performed when significance was observed. The sta-
tistical analysis was conducted using SigmaStat sta-
tistical software for Windows, version 2.03 (Systat 
Software, Inc.)   
Results 
Neurotrophin IHC expression 
 BDNF IHC expression was evaluated at 10th, 21st, 
42nd, and 80th postnatal days. BDNF positive cells 
showed a significant reduction along the postnatal 
days analyzed (F3=7.907, P<0.001, Fig.1 and Fig. 4). 
BDNF peak expression was obtained at P10 (178 ± 20 
cells), immunostaining was present mainly in somas 
of ~15 μm of diameter (Fig. 1a). By P21, the number of 
BDNF positive cells decreased (36 ± 14 cells) signifi-
cantly (t=4.144, P<0.001, Multiple Comparison Pro-
cedures, Bonferroni´s t-test) in comparison with P10 
(Fig. 1b). BDNF positive cells (80 ± 23, Fig. 1c) at P42 
were significantly different than in P10 (t=2.875, 
P=0.032, Bonferroni´s t-test). At P80, BDNF positive 
cells were significantly reduced (23 ± 9) in comparison 
with P10 (t=4.516, P<0.001, Bonferroni´s t-test). There 
were no differences between cells detected at P21 vs. 
P42 (t=1.807, P=0.449, Bonferroni´s t-test); P42 vs. P80 
(t=2.331, P=0.135, Bonferroni´s t-test) and P21 vs. P80 
(t=0.519, P=1.000, Bonferroni´s t-test; Fig. 1d). There 
were not cells detected in control sections for IHC 
(data not shown). 
IHC expression of Neurotrophin 4/5 in the 
striatum evaluated at P10, P21, P42, and P80 dis-
played significant differences in the postnatal days 
evaluated (F2=4.860, P=0.011, Fig 2 and Fig. 4). We did 
not see any NT-4/5 IHC expression at P10 (Fig. 2 a). 
Nevertheless, NT-4/5 expression increased at P21 
(234 ± 30 cells, Fig. 2 b). By P42, NT-4/5 stained cells 
(98 ± 21) showed a significant reduction (t=3.074, 
P=0.010, Bonferroni´s t-test) in comparison with P21 
(Fig. 2 c). No significant differences were observed at 
P80 (144 ± 28 cells, Fig. 2d and Fig. 4) in comparison Int. J. Biol. Sci. 2009, 5 
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with P21 (t=1.874, P=0.198, Bon-
ferroni´s t-test) or P42 (t=1.329, 
P=0.568, Bonferroni´s t-test). NT-4/5 
immunostaining was mainly somatic 
in each evaluated age. No cells were 
detected in control sections for IHC 
were primary antibody was omitted 
(data not shown). 
NT-3 expression was somewhat 
different from the other two neuro-
trophins evaluated. At P10 and P21, 
cell staining was circumscribed to 
neuronal bundles (Fig. 3 a, and b). 
Somatic expression was observed by 
P42 (121.28 ± 18) and P80 (89.6 ± 17.5), 
without significant differences (t  55= 
1.211, P = 0.231) in the NT-3 positive 
cells (Fig. 3 c and d). No cells were 
detected in control sections for IHC 
where primary antibody was avoided 
(data not shown).
 
 
 
Figure 1. BDNF immunostaining detection at the neostriatum. (a) At P10, BDNF expression was higher. The 
staining was restricted to the cytoplasm of small cells (~15μm). (b) Although the staining was considerably reduced by P21, 
it was restricted to cell somas. (c) The figure shows BDNF staining by P42. (d) At P80, there was a reduction in BDNF 
expression. Scale bar 160 μm. 
 
Figure 2. NT-4/5 immunostaining 
detection at the neostriatum. (a) At 
P10 striatal tissue did not show NT-4/5 
immunostaining. (b) On P21, NT-4/5 
showed its highest staining in cell bodies of 
~15μm (arrows) although they can be seen 
in cell somas of about ~25μm as well (ar-
rowheads). At P42 (c) and P80
 (d) NT-4/5 
did not change its expression between 
those two postnatal days, but when NT-4/5 
positive cells were compared between P42 
and P21, the staining was significantly dif-
ferent (see the text for details). Scale bar 
160μm. 
 Int. J. Biol. Sci. 2009, 5 
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Figure 3. NT-3 immunostaining detection at the neostriatum. At P10 and P21 (a, b), NT-3 immunostaining was 
restricted to the neural bundles (arrows). At P42
 (c) and P80 (d) the staining was found in the cell somas of ~15 μm (arrows) 
and big cells of ~25μm of diameter (arrowheads). Scale bar 160μm. 
 
A summary of neurotrophins expression in all 
developmental times evaluated is illustrated in Figure 
4. 
 
Figure 4. Number of immunostained cells for 
BDNF, NT-3 y NT-4/5 in the postnatal neostriatum. 
The bars show the number of stained cells for BDNF (white 
bar), NT-3 (dense bar) and NT-4/5 (sparse bar). BDNF, NT-3 
and NT-4/5 staining displayed significant differences 
(F3=7.907, P<0.001; t 55= 1.211, P = 0.231; and F2=4.860, 
P=0.011, respectively) in their postnatal expression. 
p=0.01*, p<0.001** 
 
Neurotrophins relative mRNA level expression 
 It is known that neurotrophins expression is low 
and varies along the postnatal development; therefore 
to determine whether IHC staining of neurotrophins 
was correlated with gene expression, RT-PCR tech-
nique was carried. We examined relative mRNA lev-
els of NGF, BDNF, NT-3 y NT-4/5, at P10, P21, and 
P42.  β-actin was used as a housekeeping gene and 
mRNA level of each neurotrophin was normalized 
with  β-actin endogenous expression. Neurotrophins 
mRNA levels were present in all postnatal ages 
evaluated (Fig. 5), although theirs mRNA levels varies Int. J. Biol. Sci. 2009, 5 
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in each age. mRNA levels of NGF did not change over 
the evaluated period (F2=5.119, P=0.060). mRNABDNF 
levels exhibited a significant reduction (F2=29.712, 
P<0.001) at P21 and P42 in comparison with P10 (P10 
vs. P21, t=5.135, P<0.006; P10 vs. P42, t=7.547, P<0.001; 
Bonferroni´s t-test). mRNANT-3 and mRNANT-4/5 levels 
did not display any significant difference (F2= 3.213, 
P=0.113; F2=2.289, P=0.183 respectively) at the evalu-
ated days.  
 
 
Figure 5. Relative RT-PCR of neurotrophins mRNA 
in striatal tissue from mice at P10, P21 and P42. The 
upper panel shows representative PCR products of neu-
rotrophins from 2 different mice at P10, P21, P42 stained 
with sybr green on a 2 % agarose electrophoresis gel. The 
lower panel displays data for neurotrophins mRNA from 
mice striatum at P10 (squares, n=3), P21 (ellipses, n=3) and 
P42 (triangles, n=3). Data were analyzed by measuring the 
area and density of the electrophoresis bands and are ex-
pressed as arbitrary densitometry units.  
Discussion 
 Neurotrophins are trophic factors whose actions 
are crucial for differentiation, survival and the or-
ganization of neuronal connections during postnatal 
development. Previous studies have revealed low 
levels of neurotrophin mRNAs in the striatum [1-9]. 
These earlier findings prompted us to elucidate neu-
rotrophin protein temporal expression in normal stri-
atal tissue, in attempts to better understand striatal 
abnormalities in which the lack of trophic factors 
during development may underlie degenerative dis-
eases like Parkinson or Huntington diseases. In the 
present study we show that in mice dorsal neostria-
tum, temporal neurotrophin IHC expression at post-
natal days 10th, 21st, 42nd and 80th is differential. We 
observed that when BDNF was already expressed in 
the neostriatum, NT-3 was expressed in the corticos-
triatal bundles and NT-4/5 staining was absent. With 
neurotrophin relative RT-PCR analysis, we observed 
that temporal expression of BDNF was different in 
comparison with NGF, NT-3 and NT-4/5.  
Temporal and spatial IHC expression of neuro-
trophins at the postnatal striatum 
  Under our experimental conditions, BDNF was 
the only neurotrophin IHC expressed at P10 and de-
clined with increasing postnatal age. BDNF is highly 
expressed during embryonic period and its expres-
sion changes during brain development [3]. Our re-
sults for BDNF protein expression correlate well with 
the presence of its neurotrophin receptor mRNATrkB in 
the neostriatum, which is highly expressed during 
embryonic development and declines at postnatal 
ages [20]. It has been demonstrated that neurons as 
well as glial cells in the striatum exhibit BDNF im-
munoreactivity [21] therefore, BDNF positive cells in 
our IHC experiments can be either type of cell.  
NT-3 displayed expression in striatal bundles at 
P10 and P21 and in striatal cells at P42, sustaining its 
l e v e l  o f  I C H  e x p r e s s i o n  u p  t o  P 8 0 .  T h i s  i s  t h e  f i r s t  
report in mice striatal tissue documenting differences 
in spatial expression of NT-3 at P10 and P21, where it 
was circumscribed to neuronal bundles. It has been 
recognized that, NT-3 is anterogradely transported 
from the cortex similar to BDNF, consequently, NT-3 
expression in the neostriatal bundles at P10 and P21 
may represent anterograde transport of NT-3 from the 
cortex as it has been suggested to occur [22]. In an 
earlier report, it was demonstrated that NT-3 mRNA 
is highly expressed in developing neurons in the 
cingulate cortex. That expression was transient during 
early stages of development and later the expression 
was seen in the hippocampus, supporting the notion 
that NT-3 promotes the development of cells that are 
anatomically connected [23]. NT-3 influence on stri-
atal function may be related to different neuronal 
populations than those affected by BDNF. Its tempo-
ral expression also suggests that, NT-3 is not neces-
sary as a differentiation or survival factor for striatal 
cells. In addition NT-3 activates a different type of 
neurotrophin receptors, the TrkC receptors [24]. Al-
ternatively, NT-3 may influence the same population 
BDNF affects during another developmental time as a 
result of different developmental strategies and de-
velopmental speed. Int. J. Biol. Sci. 2009, 5 
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NT-4/5 is expressed in the neostriatum, when 
BDNF is declining (Fig. 2 and 4). NT- 4/5 should ar-
rive to the neostriatum between postnatal day 10th 
and 21st, however, it is not known where the NT-4/5 
is coming from, or if it is produced inside of the nu-
cleus by neostriatal cells. Nevertheless, differences in 
temporal expression between BNDF and NT-4/5 are 
important to note, because both neurotrophins acti-
vate the same TrkB receptor [24]. It is possible that the 
actions of both neurotrophins are not the same, or 
NT-4/5 actions may substitute for BDNF actions on 
striatal cells. Alternatively, each neurotrophin may 
affect distinct neuronal populations at different de-
velopmental stages. Other studies have documented 
that NT-4/5 is not necessary for early postnatal de-
velopment of the neostriatum, still this neurotrophin 
is found all over the brain [25]. 
The developmental differences in neurotrophins 
temporal expression in the mice striatum may reflect 
the requirements of diverse group of cells for specific 
trophic factors at different postnatal stages, or it may 
suggest that every cellular group depends upon the 
presence of different neurotrophins at several stages 
of the postnatal development. 
Neurotrophins mRNA expression in postnatal 
striatum 
To establish whether the expression of neuro-
trophins detected by IHC procedure was a conse-
quence of gene expression, the mRNA levels of NGF, 
BDNF, NT-3, and NT-4/5, were evaluated at P10, P21 
and P42. P80 was omitted from this analysis because 
there were no differences in neurotrophins expression 
between P42 and p80 in IHC experiments. Al-
though β-actin was used as internal standard; we in-
cluded NGF as a positive control because it is recog-
nized that NGF mRNA levels are high between P2 
and P30 [4]. 
mRNANGF was high and remained high at all 
ages evaluated as reported previously [4].This result 
was important to show that RNA was not degraded 
and PCR was working correctly. 
  BDNF presence in the neostriatum has been 
controversial due to the lack of specific antibodies; 
nevertheless it has been detected by the ELISA tech-
nique [8]. In our experiments, mRNABDNF levels were 
evaluated at P10, P21, and P45. mRNABDNF expression 
was low and reduced with time in agreement with 
our IHC results. In another study mRNA BDNF showed 
its maximal level by the third postnatal week (~P21) 
when the PCR was carried out with the RNAse pro-
tection technique [6, 7], hence discrepancies in the 
expression level obtained in the present study may 
due to differences in the experimental procedure, still 
our data are in consonance with those reporting that 
BDNF presence in the striatal tissue declines with 
time [3]. 
NT-3 expression level of its mRNA is regulated 
differentially in comparison to BDNF, and has been 
reported that mRNANT-3 levels are constant during 
postnatal development [7]. In our experimental con-
ditions after normalizing to the housekeeping gene, 
mRNANT-3 expression at P10, P21, and P42 did not 
exhibit any statistical change, which agrees with pre-
vious experimental reports [6, 7]. In light of our IHC 
experiments, we believe that part of the mRNANT-3 
expression comes from mRNA of corticostriatal fibers, 
although we can not ruled out changes due to sample 
processing or biological changes (see below). 
We did not observe significant changes in the 
mRNANT-4/5  level expression in the postnatal days 
evaluated. Although with IHC procedure there was 
no expression of NT- 4/5 at P10. It has been reported 
that NT-4/5 is expressed in low amounts by postnatal 
development [25] and increases in adult rodents [9, 
12]; therefore, differences between mRNA and IHC 
expression of NT-4/5 may be due to insufficient levels 
of mRNA for protein translation (see below).  
Comparing our mRNA results vs. our IHC data, 
mRNABDNF levels followed the same expression pat-
tern than those obtained with IHC procedures. 
However, NT-3 showed high expression levels at P10 
and P21 with the RT-PCR technique but not with IHC. 
mRNANT-4/5 expression level was also observed at P10 
but not in the tissue processed with the IHC protocol. 
It is known that expression levels of mRNA and pro-
tein may vary in the cells, this could be due to multi-
ple factors, e.g. low levels of protein expression, 
technological sensitivities, sample processing, ana-
tomical origin of tissue and biological differences 
between transcript and protein abundance. A previ-
ous study showed that protein expression does not 
always correlate with expression levels of mRNA [26]. 
There are several possible explanations for these dis-
crepancies like post-transcriptional and 
post-translational modifications; in addition, proteins 
may have different half-lives [27]. Gene expression 
analysis is more sensitive than immunocytochemical 
procedures; therefore it is possible that genes ex-
pressed in our study are at levels not high enough for 
translated protein expression detected by IHC. Satis-
factory immunostaining requires preservation of 
protein tertiary structure in the region of the relevant 
ep it o p es [ 2 8]  an d it  m ay  b e t h at  so m e  o f n e uro t ro -
phins antibodies are less immunoreactive than others. 
It is hoped that continued improvements in 
commercially available antibodies, could further elu-
cidate the relationship between mRNA levels and Int. J. Biol. Sci. 2009, 5 
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corresponding protein expression. In addition to the 
comparison of IHC and mRNA levels by RT-PCR, 
there will be the need for further evaluation utilizing 
techniques such as in situ hybridization, western 
blotting, microarray and proteomic analysis, to have a 
better idea about neurotrophins expression through 
all development. 
Functional implications of neurotrophins in the 
postnatal striatum 
 Changes in neurotrophic factors during postna-
tal development may reveal differential nourishment 
requirements for cell populations in the neostriatum. 
BDNF is transported from the cortex to the neostria-
tum along the corticostriatal pathway where it has a 
trophic effect on medium spiny neurons (MSN) [6, 
29], besides its function in cell survival, BDNF induces 
neuronal differentiation in neurons positive to cal-
bindin [30] and DARPP-32 [31], specific markers for 
MSN. Actually, there is a reduction in calbindin and 
DARPP-32 positive neurons in BDNF knock out mice 
[32, 33]. In addition, there is an increase in apoptotic 
death during development in animals that do not ex-
press TrkB receptors [32] which are those targeted by 
BDNF. However, its expression in postnatal and adult 
tissue may be linked to other functions that require 
low amounts of BDNF such as modulation of synaptic 
transmission. 
  The presence of NT-3 in striatal tissue is not 
surprising, because this neurotrophin exhibits neuro-
trophic effects on striatal, cortical, and nigral neurons 
and increases the number of GABAergic and cal-
bindin positive neurons similar to BDNF [30]. This 
neurotrophin also promotes survival and differentia-
tion of DARPP-32 positive neurons, increases their 
neurites and somatic area [33]. Notably, NT-3 can be 
found in glial cells [34], as well as in white matter [35]. 
In our studies, NT-3 was expressed in the neostriatal 
bundles at P10 and P21; we do not know if NT-3 is 
synthesized in glial cells, nonetheless, the presence of 
this neurotrophin in corticostriatal bundles suggest 
that, NT-3 may arrive to the striatum by anterograde 
transport from cortex and perhaps there is an interac-
tion between neuronal fibers and glial cells at the 
neostriatum [22]. 
  NT-4/5 temporal expression at P21, P42 and 
P80, suggests a possible use of this neurotrophin in 
therapeutic manipulations because, it has been dem-
onstrated that NT-4/5 increases the survival of 
GABA, calbindin and calretinin positive neurons in 
the neostriatum, and shares several of the BDNF 
neurotrophic effects because, it also acts on TrkB re-
ceptors [24, 30]. Therefore, if BDNF exhibits a synthe-
sis failure, which has been demonstrated in some de-
generative illness [14], TrkB receptors might be acti-
vated with NT-4/5 to protect medium spiny neurons 
from cell death. Nevertheless this stimulation should 
be given in early phases of cellular harm, before TrkB 
receptors reduce their expression due to neuronal 
damage [36]. Perhaps early stimulation with NT-4/5 
will stop TrkB receptor decrement.  
  BDNF and NT-3, but not NT-4/5, regulates 
soma morphology in medium spiny neurons without 
changing GAD immunostaining or mRNAGAD ex-
pression [13]. It has been demonstrated that BDNF 
and NT-4/5 control different functions in the same 
cell type, for example BDNF but not NT-4/5, increases 
the somatic area in neurons [37-39]. According to our 
results (Fig. 4), BDNF and NT-4/5 may act on differ-
ent neuronal populations; however, both neurotro-
phins may affect the same cell population at different 
times due to changes in their expression time course. 
Although both neurotrophins activate TrkB receptors, 
their temporal expression is different, and NT-3 acti-
vates TrkB receptors in a lower proportion and acti-
vates TrkC receptors as well [40].  
Conclusions 
  As neurotrophins have important actions on 
neuron’s survival, differentiation and maintenance, 
any failure in spatial and temporal neurotrophic sup-
ply may harm neostriatal cells; hence, the knowledge 
about their postnatal expression shall be crucial to 
understanding those pathologies afflicting the 
neostriatum early in development. In the present 
study, the most important result was to visualize dif-
ferences in neurotrophin´s temporal expression in the 
neostriatum. In particular, our data supporting NT-3 
protein expression in fiber bundles opens the possi-
bility of revising its function in the neostriatum as 
well NT-4/5 function, even though it is unclear which 
cells NT-4/5 is synthesized.  
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